A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura

Baştürk, Abdulkadir; Sayin, Serhat; Erkurt, Mehmet Ali; Sarıcı, Ahmet; Ekinci, Omer; Kum, Asli; Berber, İlhami; Korkmaz, Serdal; Doğan, Ali; Ulaş, Turgay; Kuku, İrfan; Eser, Bülent; Altuntaş, Fevzi

doi:10.1016/j.transci.2021.103246

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another, the 6-month response rate and rate of splenectomy were no different among 12 patients who received TPE plus prednisone compared to seven patients treated with prednisone alone (Buskard, 1998). In a case series of 17 patients treated with corticosteroids, IVIG, and TPE, nine patients (53%) had complete response (≥100 Â 10 9 /L), seven patients (41%) had partial response (30-100 Â 10 9 /L), and one patient (6%) had no response (Basturk, 2021). In an administrative claims database study, TPE use (n = 372; <1% of ITP cases) was associated with higher disease severity (OR 32.76; P<.001) and longer hospital stay (13 vs. 4 days; P<.001; Makhani 2022).…”

Section: Rationale For Therapeutic Apheresismentioning

confidence: 89%

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Connelly‐Smith

Alquist

Aqui

et al. 2023

J of Clinical Apheresis

218

View full text Add to dashboard Cite

The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis (TA) in human disease. In the Ninth Edition, the JCA Special Issue Writing Committee has incorporated systematic review and evidence-based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease or medical condition. The Ninth Edition of the JCA Special Issue comprises 91 fact sheets and

show abstract

Section: Rationale For Therapeutic Apheresismentioning

confidence: 89%

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Connelly‐Smith

Alquist

Aqui

et al. 2023

J of Clinical Apheresis

218

View full text Add to dashboard Cite

show abstract

“…Another small study found TPE to be a useful adjunct therapy in preparation for splenectomy, although its individual effects would not have been sufficient to hold off splenectomy 13 . A study conducted by Basturk et al found potential benefit for TPE in ITP patients when combined with first‐ and second‐line therapies, such as prednisone, splenectomy, IVIG, and rituximab; partial and complete responses were achieved in 41% and 52% of patients respectively 14 . Some studies reported that TPE decreases the likelihood of needing splenectomy, while others have claimed that TPE should precede splenectomy as a preparative treatment 12,13 .…”

Section: Discussionmentioning

confidence: 99%

“…13 A study conducted by Basturk et al found potential benefit for TPE in ITP patients when combined with first-and second-line therapies, such as prednisone, splenectomy, IVIG, and rituximab; partial and complete responses were achieved in 41% and 52% of patients respectively. 14 Some studies reported that TPE decreases the likelihood of needing splenectomy, while others have claimed that TPE should precede splenectomy as a preparative treatment. 12,13 In summary, current literature describes TPE use through small case series and case reports only.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic plasma exchange practices in immune thrombocytopenia related hospitalizations: Results from a nationally representative sample

Makhani

Schwartz

Vasović

et al. 2022

J of Clinical Apheresis

View full text Add to dashboard Cite

Per the American Society for Apheresis, therapeutic plasma exchange (TPE) is a Category III indication in the management of immune thrombocytopenia (ITP). This nationally representative study evaluates TPE utilization in hospitalized adults with a primary admission diagnosis of ITP. Hospitalizations with ITP as the primary admitting diagnosis were analyzed from the 2010 to 2014 National Inpatient Sample, the largest all-payer inpatient database in the United States.Univariate and multivariable logistic regressions were used to determine clinical outcomes in ITP patients undergoing TPE. Sampling weights were applied to

show abstract

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions

Jacobs,

Booth,

Raza

et al. 2024

American J Hematol

View full text Add to dashboard Cite

The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.

show abstract

A multicenter retrospective analysis on therapeutic plasma exchange in immune thrombocytopenic purpura

Cited by 4 publications

References 5 publications

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Therapeutic plasma exchange practices in immune thrombocytopenia related hospitalizations: Results from a nationally representative sample

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions

Contact Info

Product

Resources

About